Bup on drug test
Pro Research Analysisby 
Searched over 200M research papers
Buprenorphine Detection in Drug Tests: Methods and Efficacy
Introduction to Buprenorphine (BUP) Detection
Buprenorphine (BUP) is widely used in the treatment of opioid dependence. However, its potential for abuse necessitates reliable methods for monitoring its use. Various studies have explored different matrices and techniques for detecting BUP, each with its own advantages and limitations.
Development of Rapid Test Strips for Buprenorphine Detection
Recent advancements have led to the creation of rapid test strips for BUP detection. These test strips utilize monoclonal antibodies (MAbs) to achieve high sensitivity and specificity. The test strips developed have a limit of detection (LOD) of 12.5 ng/mL and do not cross-react with other drugs at physiological levels, making them effective for monitoring BUP in urine specimens1. This method allows for timely and effective detection, crucial for controlling the amount of BUP used in therapy.
Urine vs. Oral Fluid for Buprenorphine Compliance Monitoring
When comparing urine (UR) and oral fluid (OF) for BUP compliance monitoring, urine has been found to be superior. A study involving 260 paired OF and UR specimens revealed that BUP and its metabolites were more frequently detected in urine. Specifically, 97% of patients prescribed BUP tested positive in urine compared to 78% in oral fluid. Additionally, urine testing was more effective in detecting undisclosed use, with a higher rate of positive results for BUP and its metabolites2. This suggests that urine is the preferred matrix for both compliance monitoring and detecting illicit drug use.
Evaluation of Buprenorphine LUCIO Immunoassay
The BUP LUCIO Nal Von Minden screening assay has been evaluated for its effectiveness in workplace drug testing programs. This immunoassay, when compared to gas chromatography-mass spectrometry (GC-MS), showed high sensitivity and specificity at a 5 ng/mL cut-off concentration. The overall agreement between the immunoassay and GC-MS was 94%, indicating that the LUCIO assay is reliable for BUP screening in urine samples3. This method provides a practical and accurate option for workplace drug testing.
Clinic-Based Treatment and Monitoring of Opioid-Dependent Patients
In the context of treating opioid-dependent HIV-infected patients, clinic-based BUP treatment has shown significant benefits over referral to an opioid treatment program. Patients receiving clinic-based BUP had higher participation rates in opioid agonist therapy and fewer positive test results for opioids and cocaine. Additionally, these patients attended more HIV primary care visits, although there were no significant differences in antiretroviral therapy use or changes in HIV RNA levels and CD4 cell counts between the two groups4. This approach highlights the importance of integrated care in improving treatment outcomes for opioid-dependent patients.
Conclusion
Effective detection and monitoring of buprenorphine use are critical in both clinical and workplace settings. Rapid test strips, urine testing, and reliable immunoassays like the BUP LUCIO Nal Von Minden screening assay provide robust methods for ensuring compliance and detecting abuse. Additionally, integrated clinic-based treatment models offer significant advantages in managing opioid dependence, particularly in vulnerable populations such as HIV-infected patients. These advancements collectively contribute to better management and outcomes in opioid dependence treatment.
Sources and full results
Most relevant research papers on this topic
Development of test strips for rapid buprenorphine detection in vitro.
This study developed rapid test strips using monoclonal antibodies for buprenorphine detection in urine specimens, providing sufficient sensitivity and specificity for monitoring dosages in opioid dependence treatment.
In Vitro StudyUrine is superior to oral fluid for detecting buprenorphine compliance in patients undergoing treatment for opioid addiction.
Urine is the preferred matrix for detecting both buprenorphine compliance and undisclosed use in patients undergoing opioid addiction treatment.
Observational StudyEvaluation of buprenorphine LUCIO immunoassay versus GC-MS using urines from a workplace drug testing program.
The BUP LUCIO Nal Von Minden screening assay provides adequate sensitivity and specificity for BUP screening in urine samples using a cut-off concentration of 5 ng/mL.
Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program
Clinic-based BUP treatment for HIV-infected, opioid-dependent patients facilitates access to opioid agonist therapy and improves substance abuse treatment outcomes compared to referred treatment.
RCT
Highly CitedTherapeutic Drug Monitoring in Buprenorphine/Naloxone Treatment for Opioid Use Disorder: Clinical Feasibility and Optimizing Assay Precision
Therapeutic drug monitoring (TDM) is feasible for buprenorphine/naloxone maintenance treatment of opioid use disorder, with simple adjustments to assay conditions enhancing BUP recovery.
Buprenorphine and major metabolites in blood specimens collected for drug analysis in law enforcement purposes.
The developed method effectively quantifies buprenorphine and its major metabolite, NBUPG, in blood samples for law enforcement purposes.
Determination of buprenorphine, norbuprenorphine and naloxone in fingernail clippings and urine of patients under opioid substitution therapy.
The developed method successfully determines buprenorphine, norbuprenorphine, and naloxone in urine and nails from former heroin users under opioid substitution therapy.
Comparative Analyses of Three Point-of-Care Urine Drug Test Devices' Performance Characteristics for Use in Ambulatory Clinic Settings.
The Profile-V MEDTOX Scan demonstrated the best overall sensitivity and specificity compared to reference methods, but the best device may depend on patient population and drugs of interest.
Observational StudyBuprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.
Buprenorphine/naloxone and methadone both effectively treat opioid dependence without major concerns for liver damage during the initial 6 months of treatment.
RCT
Large Human TrialHighly CitedA Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone
Buprenorphine/naloxone treatment for opioid-use disorder shows improvements in abstinence and high compliance, potentially mitigating fears of diversion in comprehensive programs.
Literature ReviewHighly Cited